Imugene Limited

Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines.

Latest Media Releases

Imugene, Investor Presentation

10/01/2019 09:45:00

HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY Investment Highlights Novel immuno-oncology B-cell peptide vaccine technology Outstanding scientific provenance from leading U.S. and European un…

Latest News